Alto Neuroscience Reports Topline Results from Phase 2b Trial for ALTO-100

Alto Neuroscience, Inc. (NYSE: ANRO) recently disclosed the outcomes of its Phase 2b clinical trial evaluating ALTO-100 as a potential treatment for Major Depressive Disorder. The results, revealed through a press release on October 22, 2024, highlighted that the trial did not achieve its primary endpoint based on the change from baseline in Montgomery-Åsberg Depression Rating Scale when compared to a placebo.

Despite missing the primary endpoint, the press release indicated that ALTO-100 displayed a favorable safety and tolerability profile consistent with previous study findings. Interested parties can access a copy of the detailed press release attached to this Current Report on Form 8-K under Exhibit 99.1.

As part of disclosure requirements, Alto Neuroscience also furnished a Cover Page Interactive Data File (alongside the Inline XBRL document) as Exhibit 104, meeting the obligations of Item 9.01 – Financial Statements and Exhibits.

The regulatory filing also confirmed that Alto Neuroscience remains compliant with the necessary provisions as stipulated by the Securities and Exchange Act of 1934. The report was officially signed on October 22, 2024, by Amit Etkin, M.D., Ph.D., who serves as the President and Chief Executive Officer of Alto Neuroscience, Inc.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Alto Neuroscience’s 8K filing here.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.